Page 2 - Glp1

Ozempic use linked to lower depression and anxiety risk, says Lancet study

A large-scale study finds semaglutide may lower the risk of depression and anxiety, adding an unexpected mental health dimension to its known physical health benefits

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Can Ozempic and similar weight loss drugs cause hair loss? Experts explain

Experts explain the science behind hair loss reports, noting that the shedding is usually temporary and linked to how the body responds to rapid weight loss

Centre increases monitoring of weight-loss drugs, flags safety concerns

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

Govt issues guidelines on GLP-1 drugs use, risks, and regulations

To prevent unauthorised sale, unsupervised use, and other malpractices, the Drug Controller of India has intensified its regulatory surveillance, warning that the drugs can lead to serious side effect

As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices

Drugmaker cuts prices of injectable semaglutide brands to expand access in India, but says no similar price reduction is planned for oral semaglutide brand Rybelsus

As India's weight management market expands, misleading ads risk rises

A week before semaglutide's patent expiry, the CDSCO issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law

India gets cheap GLP-1 drugs: What you must know before trying it

India's 'cheap Ozempic moment' is here as semaglutide prices fall sharply, but doctors warn against misuse and stress careful evaluation before using these weight-loss injections

Govt intensifies checks on illegal sale, misuse of GLP-1 weight-loss drugs

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

What happens after stopping GLP-1 drugs like Ozempic? Study reveals

A large real-world study finds patients stopping semaglutide or tirzepatide may not regain as much weight as expected, aided by treatment switches, restarts, and lifestyle support

Fake obesity drugs are booming globally: Lancet report raises alarm

A Lancet report warns counterfeit weight-loss injections like Ozempic and Mounjaro are spreading globally, driven by high demand and prices, raising serious risks for patients

CDSCO asks drugmakers to stop GLP-1 obesity awareness ad campaigns

Drug regulator warns pharma companies that obesity awareness drives linked to GLP-1 drugs could amount to misleading promotion of prescription medicines

Indian CDMOs expand capacity as demand for complex drug work rises

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

GLP-1 drugs may fight addiction across every major substance: Study

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction

GLP-1 drugs: How to lose the fat without losing your muscle, shares expert

A US-based gastroenterologist warns that while GLP-1 drugs help shed kilos, they may also reduce lean muscle mass if not paired with strength training and adequate protein intake

Ozempic and other weight-loss drugs: Cost, risks, who really needs them

As Ozempic and other GLP-1 drugs gain popularity, experts explain who qualifies, the real health benefits, potential risks, side effects, and why supervision is critical

Biopharma Shakti shows India focusing on being biopharma hub: Biocon's Shaw

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase

Ozempic may slow arthritis progression beyond weight loss, study finds

A new study finds semaglutide drugs like Ozempic may slow osteoarthritis by directly improving cartilage health, with benefits seen even when weight loss is not the driver

Serena Williams reveals GLP-1 weight loss journey in Super Bowl 2026 ad

The tennis legend says she lost 15 kg using a GLP-1 medication after struggling with post-pregnancy weight, revealing the journey in a Super Bowl 2026 ad for telehealth firm Ro

India-EU trade deal likely to help GLP-1 therapies become cheaper

India-EU FTA to lower tariffs on pharma, potentially making GLP-1 therapies like semaglutide cheaper and boosting adoption among diabetics in India